Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX Stock Outperforms Industry Image Source: Zacks Investment Research The ...

This Press Release contains forward-looking statements and information ("forward-looking statements") within the meaning of applicable Canadian securities laws. The forward-looking statements ...

Counterpart Health, MEDITECH, and Suki are using Vertex AI Search for healthcare to improve clinicians' access to information and gain a more comprehensive view on patient health SUNNYVALE, Calif.

Arizona State Retirement System boosted its position in shares of Vertex, Inc. (NASDAQ:VERX – Free Report) by 7.3% during the fourth quarter, according to the company in its most recent Form 13F ...

The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the ...

The Trump administration’s cuts to a global AIDS relief program threaten to upend rollout of a groundbreaking HIV prevention ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

LAS VEGAS—At the HLTH conference in 2023, Google's cloud division unveiled new artificial-intelligence-powered search capabilities to help doctors and nurses quickly access patients' clinical ...

Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and genetic therapies – and has just chalked up fast-track status from the FDA for a cell-based ...